CoinInsight360.com logo CoinInsight360.com logo
America's Social Casino

crypto.news 2025-06-18 05:31:45

Nasdaq-listed firm announces $50M Hyperliquid reserve — will HYPE rise further?

A Nasdaq-listed biotech company is betting big on crypto with a $50 million move into Hyperliquid’s HYPE token. According to a June 17 press release from Eyenovia, Inc., a U.S.-based ophthalmic technology firm, the company has secured $50 million in private equity financing to accumulate over 1 million Hyperliquid ( HYPE ) tokens. With this move, Eyenovia becomes the first publicly traded U.S. company to hold HYPE in its treasury and operate as a Hyperliquid blockchain validator. The funding deal includes convertible preferred shares and warrants, which could raise up to $150 million if fully exercised. Alongside the announcement, Eyenovia named Hyunsu Jung as chief investment officer and board member to oversee the new digital asset strategy. “We’re pleased to join the growing number of companies adopting cryptocurrency treasury strategies,” said chief executive officer Michael Rowe. “We believe this move supports long-term capital appreciation and shareholder value.” You might also like: Can Hyperliquid rise to $50 in June? Jung called HYPE “the most robust digital asset,” citing Hyperliquid’s rapid growth and leading onchain revenue. HYPE ranks as the 12th-largest cryptocurrency by market cap, having surged 380% from its April low to an all-time high of $45.57 on June 16. At press time, HYPE is trading at $40.24, down 11% from its peak. Hyperliquid, a high-speed Layer 1 blockchain optimized for perpetuals trading, has seen a wave of adoption. In the past 30 days, it has accounted for 60% of the total onchain perps volume, according to data from a Dune Analytics dashboard. Monthly perps volume has topped $250 billion, making it a strong competitor to centralized exchanges such as Binance. Eyenovia plans to execute a staking strategy with its HYPE holdings and use Anchorage Digital to secure its assets. In addition, the company will rebrand to “Hyperion DeFi” and change its ticker symbol to HYPD. Eyenovia will keep working on its flagship Optejet eye treatment device, which is expected to receive FDA registration by September, while branching out into cryptocurrency. If other public companies follow Eyenovia’s lead, Hyperliquid could see a sharp increase in token demand and network effects, potentially positioning it as a top 10 blockchain by market capitalization. Read more: No VC, $1B Trades, and a 300% Rally — what makes Hyperliquid crypto tick?

阅读免责声明 : 此处提供的所有内容我们的网站,超链接网站,相关应用程序,论坛,博客,社交媒体帐户和其他平台(“网站”)仅供您提供一般信息,从第三方采购。 我们不对与我们的内容有任何形式的保证,包括但不限于准确性和更新性。 我们提供的内容中没有任何内容构成财务建议,法律建议或任何其他形式的建议,以满足您对任何目的的特定依赖。 任何使用或依赖我们的内容完全由您自行承担风险和自由裁量权。 在依赖它们之前,您应该进行自己的研究,审查,分析和验证我们的内容。 交易是一项高风险的活动,可能导致重大损失,因此请在做出任何决定之前咨询您的财务顾问。 我们网站上的任何内容均不构成招揽或要约